Extraneal
(Icodextrin)ApprovedSmall molecule
Extraneal is one of 56 small molecule programs targeting Tics. It is currently in Approved.
3
Indications
8
Total Trials
1
Active Trials
55
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
114 competitors in Tics
#DrugCompanyPhaseTrials
1Extraneal
VVantive Health LLC
Approved
Sodium Valproate
AstraZenecaPhase 3
Priftin
SanofiPhase 2
Nydrazid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Duvyzat
ItalfarmacoPhase 2
Dilaudid
RRhodes Pharmaceuticals, L.P.
Phase 2
CAB LA
GSKPhase 2
Aciphex
Akero TherapeuticsPhase 1
Invokana
WWim Janssens
Phase 1
Tylenol
KKenvue Brands
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Peritoneal Dialysis3 trials
Use of a Bimodal Solution for Peritoneal Dialysis
Completed·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 2·NCT01242904·36 enrolled
Peritonitis1 trial
Effect of Icodextrin on the Treatment Outcome of Peritoneal Dialysis Patients During Acute Peritonitis
Completed·—·Phase 4·NCT01044446·56 enrolled
1 more indication
Regulatory
FDA Approval Timeline[4]
Dec 20, 2002
EXTRANEAL
NDA NDA021321
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Icodextrin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- VVantive Health LLC